Is apvo a good buy

**Aptevo Therapeutics (APVO) is not a good buy opportunity at this time**, based on the following analysis:

1. **Financial Performance**: APVO has reported a net income of -$7.64 million and -$4.64 million for the years 2023 and 2024, respectively, indicating a worsening financial situation. The company's diluted EPS has also been negative, with values of -$1.5, -$17.38, -$53.95, -$0.5, and -$1.67 for the same periods. These figures suggest that the company is currently unprofitable.
.
2. **Revenue Growth and Product Development**: The company's revenue has shown a significant decline, with a 43.17% decrease over the past year. The company's focus on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ platform could be promising, but the lack of revenue growth and negative net income indicate challenges in translating product development into commercial success.
3. **Stock Price and Analyst Sentiment**: The stock price has experienced a substantial decline, with a 43.17% decrease over the past year. Analysts have upgraded the stock to a Zacks Rank #2 (Buy), reflecting positive sentiment towards the stock's potential for growth. However, the average price target of $9.44 suggests that analysts believe the stock has potential for growth, which may not be supported by the company's current financial performance.
4. **Market Position and Competitive Landscape**: APVO faces significant competition in the biotechnology industry, and its financials and stock price indicate that it is currently struggling to gain traction in the market.

In conclusion, Aptevo Therapeutics's current financial performance, lack of profitability, and challenging market position suggest that it is not a good buy at this time. While there is potential for growth with the company's product development, the high level of risk associated with its financials and market challenges indicate that investors should exercise caution.